2. Signaling Pathways
  3. Protein Tyrosine Kinase/RTK
  4. FGFR

FGFR

Fibroblast growth factor receptor

FGFR

Related Products

PDF 1.46 MB

FGFR (Fibroblast growth factor receptors) are the receptors that bind to members of the fibroblast growth factor family of proteins. Some of these receptors are involved in pathological conditions. A point mutation in FGFR3 can lead to achondroplasia. Five distinct membrane FGFR have been identified in vertebrates and all of them belong to the tyrosine kinase superfamily (FGFR1, FGFR2, FGFR3, FGFR4, FGFR6). The fibroblast growth factor family constitutes one of the most important groups of paracrine factors that act during development. They are responsible for determining certain cells to become mesoderm, for the production of blood vessels, for limb outgrowth, and for the growth and differentiation of numerous cell types.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-147621
    FGFR-IN-6
    		Inhibitor
    FGFR-IN-6 (Compound 5) is a FGFR inhibitor. FGFR-IN-6 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    FGFR-IN-6
  • HY-50905S
    Dovitinib-d8
    		Inhibitor
    Dovitinib-d8 is the deuterium labeled Dovitinib. Dovitinib (CHIR-258) is a multi-targeted tyrosine kinase inhibitor with IC50s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, FGFR1/FGFR3, VEGFR1/VEGFR2/VEGFR3 and PDGFRα/PDGFRβ, respectively.
    Dovitinib-d<sub>8</sub>
  • HY-159691
    IONIS-FGFR4Rx
    		Inhibitor
    IONIS-FGFR4Rx (ISIS 463588) is an antisense inhibitor of fibroblast growth factor receptor 4 (FGFR4), which is promising for research of renal diseases.
    IONIS-FGFR4Rx
  • HY-168653
    FGFR-IN-15
    		Inhibitor
    FGFR-IN-15 (compound 18i) is a pan-FGFR inhibitor with potently inhibitory activity against FGFR1-4..
    FGFR-IN-15
  • HY-174154
    INCB126503
    		Inhibitor
    INCB126503 is an orally activeM, selective FGFR2/3 Inhibitor with IC50 values of 70 nM (FGFR1), 2.1 nM (FGFR2), 1.2 nM (FGFR3), 0.92 nM (FGFR3-V555L), 0.85 nM (FGFR3-V555M) and 64 nM (FGFR4). INCB126503 suppresses FGFR signaling in vivo without causing hyperphosphatemia and shows antitumor efficacy in xenograft models harboring FGFR3 genetic alterations.
    INCB126503
  • HY-E70829
    FGFR3 V555M Recombinant Human Active Protein Kinase
    FGFR3 kinase mutations are associated with a variety of malignancies. FGFR3 V555M mutation leads to resistance to FGFR inhibitors. FGFR3 V555M Recombinant Human Active Protein Kinase is a recombinant FGFR3 V555M protein that can be used to study FGFR3 V555M-related functions.
    FGFR3 V555M Recombinant Human Active Protein Kinase
  • HY-163273
    FGFR4-IN-17
    		Inhibitor
    FGFR4-IN-17 (Compound (S)-23) is a piperazinyl diflurindan derivative containing pyridinyl. FGFR4-IN-17 is a FGFR inhibitor with IC50 values of 24.2, 16.1, 78.0, and 68.0 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively. FGFR4-IN-17 has antitumor activity.
    FGFR4-IN-17
  • HY-E70828
    FGFR3 V555L Recombinant Human Active Protein Kinase
    FGFR3 kinase mutations are associated with a variety of malignancies. FGFR3 V555L mutation leads to resistance to FGFR inhibitors. FGFR3 V555L Recombinant Human Active Protein Kinase is a recombinant FGFR3 V555L protein that can be used to study FGFR3 V555L-related functions.
    FGFR3 V555L Recombinant Human Active Protein Kinase
  • HY-P990597
    HuGAL-F2
    		Inhibitor 98.30%
    HuGAL-F2 is a human-derived antibody expressed in CHO cells, targeting FGF2. HuGAL-F2 contains a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for HuGAL-F2 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
    HuGAL-F2
  • HY-156791
    FGFR3-IN-7
    		Inhibitor
    FGFR3-IN-7 is a potent and selective FGFR3 inhibitor with IC50 value less than 350 nM. FGFR3-IN-7 can be used in research of cancer.
    FGFR3-IN-7
  • HY-160621
    CXF-009
    		Inhibitor
    CXF-009 is a selective and covalent FGFR4 inhibitor, with the IC50 of 48 nM. CXF-009 targeting Cys477 and Cys552 of FGFR4, and can be used for the study of hepatocellular carcinoma.
    CXF-009
  • HY-10331AR
    Regorafenib monohydrate (Standard)
    		Inhibitor
    Regorafenib (monohydrate) (Standard) is the analytical standard of Regorafenib (monohydrate). This product is intended for research and analytical applications. Regorafenib (BAY 73-4506) monohydrate is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC50 values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib monohydrate shows very robust antitumor and antiangiogenic activity.
    Regorafenib monohydrate (Standard)
  • HY-W801893
    FGFR1 inhibitor-13
    		Inhibitor
    FGFR1 inhibitor-13 (compound 1) is an FGFR1 inhibitor with an IC50 of 4.2 μM.
    FGFR1 inhibitor-13
  • HY-170776
    AXL/Angiokinase-IN-1
    		Inhibitor
    AXL/Angiokinase-IN-1 (compound 11b) is an AXL/triple angiokinase inhibitor, IC50=3.75 nM (AXL expression). AXL/Angiokinase-IN-1 inhibits epithelial-mesenchymal transition (EMT) in Bxpc-3, blocking lung cancer cell metastasis. AXL/Angiokinase-IN-1 also inhibits vascular and fibroblast functions, promoting apoptosis (apoptosis) in cancer cells and fibroblasts. AXL/Angiokinase-IN-1 features low toxicity and good metabolic stability.
    AXL/Angiokinase-IN-1
  • HY-E70825
    FGFR2 V564F Recombinant Human Active Protein Kinase
    FGFR2 is a receptor tyrosine kinase that is involved in many human cancers such as intrahepatic cholangiocarcinomas and hepatocellular carcinomas. FGFR2 V564F is a mutant of FGFR3. FGFR2 V564F Recombinant Human Active Protein Kinase is a recombinant FGFR2 V564F protein that can be used to study FGFR2 V564F-related functions.
    FGFR2 V564F Recombinant Human Active Protein Kinase
  • HY-158011
    FGFR3-IN-9
    		Inhibitor
    FGFR3-IN-9 (example27) is a selective FGFR3 inhibitor.
    FGFR3-IN-9
  • HY-151903S
    FGFR2/3-IN-1
    		Inhibitor
    FGFR2/3-IN-1 is a potent and selective FGFR2 and FGFR3 (FGFR) inhibitor with IC50s of 1 nM and 0.5 nM, respectively. FGFR2/3-IN-1 displays >40-fold selectivity over FGFR1/FGFR4 and other kinome. FGFR2/3-IN-1 also inhibits FGFR3 V555L and V555M mutants with IC50s of 2.7 nM and 6.1 nM, respectively.
    FGFR2/3-IN-1
  • HY-176547
    FGFR2/3-IN-3
    		Inhibitor
    FGFR2/3-IN-3 is a dual-target FGFR2/3 inhibitor with IC50s of 2.7 nM (TEL-FGFR2) and 3.9 nM (TEL-FGFR3), respectively. FGFR2/3-IN-3 has effective activity against both wild-type and mutant FGFR3. FGFR2/3-IN-3 has low CYP3A4 inhibitory effect and hERG toxicity. FGFR2/3-IN-3 improves the imbalance between chondrocyte proliferation and differentiation and promotes bone growth by inhibiting the signaling pathway mediated by mutant FGFR3. FGFR2/3-IN-3 shows a growth-promoting effect in a dwarfism mouse model and has the potential to study bone development disorder-related diseases such as achondroplasia (ACH).
    FGFR2/3-IN-3
  • HY-177668A
    Umedaptanib pegol sodium
    		Inhibitor
    Umedaptanib pegol sodium is an anti-fibroblast growth factor-2 (FGF2) aptamer. It is used for the study of neovascular age-related macular degeneration (nAMD).
    Umedaptanib pegol sodium
  • HY-50904S
    Nintedanib-d3
    		Inhibitor
    Nintedanib-d3 is the deuterium labeled Nintedanib. Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.
    Nintedanib-d<sub>3</sub>
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity